Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.67 |
| ▸ | BTK | Q06187 | 14/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | LYN | P07948 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.37 |
| ▸ | BLK | P51451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028914 | 0.90 | ESR1 (0.60) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4031188 | 0.82 | ESR1 (0.72) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4029342 | 0.82 | ESR1 (0.69) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4025963 | 0.81 | ESR1 (0.71) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4027904 | 0.81 | ESR1 (1.00) | ESR1BTKEGFRSRCCMKLR1 | |
| SCHEMBL4025780 | 0.80 | ESR1 (0.97) | ESR1BTKEGFRSRCCMKLR1 | |
| SCHEMBL4030883 | 0.80 | ESR1 (0.68) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4028868 | 0.78 | ESR1 (0.71) | ESR1BTKEGFRCMKLR1 | |
| SCHEMBL4030187 | 0.77 | ESR1 (0.61) | ESR1BTKLCKLYNEGFR | |
| SCHEMBL4027938 | 0.77 | ESR1 (0.61) | ESR1BTKLCKLYNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885BTK 896/4885LCK 1054/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885BTK 810/4885LCK 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.